Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01774968
First received: January 22, 2013
Last updated: May 30, 2014
Last verified: May 2014

January 22, 2013
May 30, 2014
February 2013
May 2014   (final data collection date for primary outcome measure)
Change from Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01774968 on ClinicalTrials.gov Archive Site
  • Proportion of Participants Achieving HbA1c of ≤6.5%; <7.0%; <7.5%; and <8.0% at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • 30-Day Adjusted Rate of Hypoglycemic Events [ Time Frame: Baseline through Week 24 ] [ Designated as safety issue: Yes ]
  • Change from Baseline to Week 24 in Body Weight [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: Yes ]
  • Change from Baseline to Week 24 in Total Daily Dose (TDD) of Insulin [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]
  • Change from Baseline to Week 24 in Fasting Plasma Glucose (FPG) Levels [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]
  • Time to Reach HbA1c Target Values [ Time Frame: Baseline through Week 24 ] [ Designated as safety issue: No ]
  • Percentage of Participants with Hypoglycemic Events [ Time Frame: Baseline through Week 24 ] [ Designated as safety issue: Yes ]
  • Change from Baseline to Week 24 in Number of Insulin Injections [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]
  • Mean Change from Baseline to Week 24 in 7-Point Self-Monitored Blood Glucose (SMBG) [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]
  • Change from Baseline to Week 24 in HbA1c based on Baseline TDD Insulin ≥2.0 units/kilogram and <2.0 units/kg [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]
  • Change from Baseline to Week 24 in 30-Day Adjusted Rate of Hypoglycemic Events based on Baseline TDD Insulin ≥2.0 units/kilogram and <2.0 units/kg [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: Yes ]
  • Change from Baseline to Week 24 in Percentage of Participants with Hypoglycemic Events based on Baseline TDD Insulin ≥2.0 units/kg and <2.0 units/kg [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: Yes ]
  • Change from Baseline to Week 24 in Body Weight based on Baseline TDD Insulin ≥2.0 units/kg and <2.0 units/kg [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
Two Treatment Approaches for Human Regular U-500 Insulin (Thrice-Daily Versus Twice-Daily) in Subjects With Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on High-Dose U-100 Insulin Therapy With or Without Oral Agents: A Randomized, Open-Label, Parallel Clinical Trial

The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
Drug: Human Regular U-500 Insulin
Administered SC
Other Names:
  • LY041001
  • Humulin R
  • Experimental: Human Regular U-500 Insulin TID
    Human Regular U-500 Insulin (U-500R) titrated based on blood glucose readings, administered subcutaneously (SC), three times a day (TID) for 24 weeks.
    Intervention: Drug: Human Regular U-500 Insulin
  • Experimental: Human Regular U-500 Insulin BID
    U-500R Insulin titrated based on blood glucose readings, administered SC, two times a day (BID) for 24 weeks.
    Intervention: Drug: Human Regular U-500 Insulin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
325
May 2014
May 2014   (final data collection date for primary outcome measure)

Major Inclusion Criteria:

  • Have type 2 diabetes mellitus World Health Organization (WHO) Classification of Diabetes
  • Have a body mass index (BMI) ≥25 kilogram per square meter (kg/m^2)
  • Have Glycated Hemoglobin A1c (HbA1c) ≥7.5% and ≤12.0%, as measured by the central laboratory at entry
  • Current U-100 insulin/analogue users on >200 and ≤600 units per day for ≥3 months at study entry and reconfirmed at randomization
  • Have a history of stable body weight for at least 3 months prior to study entry
  • Concomitant medications may include metformin (MET), dipeptidyl peptidase-4 (DPP-4) inhibitors approved for use with insulin at time of study entry (for example, sitagliptin, saxagliptin, and linagliptin), pioglitazone, and/or sulfonylureas (SUs)/glinides (repaglinide or nateglinide). Participant's oral antihyperglycemic drug (OAD) dose(s) must have been stable for ≥3 months

Major Exclusion Criteria:

  • Have type 1 diabetes mellitus or other types of diabetes mellitus apart from type 2 diabetes mellitus
  • Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine aminotransferase or aspartate aminotransferase levels ≥3 times the upper limit of the reference range
  • Have chronic kidney disease stage 4 and higher or history of renal transplantation
  • Have history of more than 1 episode of severe hypoglycemia within the 6 months prior to study entry
  • Have received insulin by continuous SC insulin infusion in the 3 months prior to study entry
  • Have received U-500R in the 3 months prior to study entry
  • Have had a blood transfusion or severe blood loss within 3 months prior to study entry or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia
  • Are taking chronic systemic glucocorticoid therapy or have received such therapy within the 4 weeks immediately prior to study entry
  • Have an irregular sleep/wake cycle
  • Have used rosiglitazone, once- or twice-daily glucagon-like peptide-1 (GLP-1) receptor agents, pramlintide, or other injectable or oral antihyperglycemic therapy not listed in the inclusion criteria in the 3 months prior to study entry. Participants may not have used once-weekly GLP-1 receptor agents in the 4 months prior to study entry
  • Have used any weight loss drugs in the 3 months prior to study entry
  • Have a history of bariatric surgery
  • Have a history of malignancy other than basal cell or squamous cell skin cancer
  • Have New York Heart Association (NYHA) Class III or IV per NYHA Cardiac Disease Functional Classification
  • Are breastfeeding or pregnant, or intend to become pregnant during the course of the study, or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT01774968
14838, B5K-US-IBHC
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP